FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Truist Lowers Price Target for Boston Scientific Corporation

      Truist has revised its price target for Boston Scientific Corporation, reducing it from $92 to $90. Despite this adjustment, the firm has maintained a Buy rating on the company's shares.

      The update was released on April 15 and is part of a larger research note that anticipates the company's fiscal first-quarter results. Boston Scientific Corporation is currently viewed as one of the more oversold stocks within the healthcare sector.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud